Trade MediciNova - MNOV CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | - | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Year Change* | N/A |
| Day's Range* | N/A |
| 52 wk Range | 1.96-4.65 |
| Average Volume (10 days) | 60.64K |
| Average Volume (3 months) | 765.08K |
| Market Cap | 103.98M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 49.05M |
| Revenue | N/A |
| EPS | -0.27 |
| Dividend (Yield %) | N/A |
| Beta | 0.83 |
| Next Earnings Date | Feb 14, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
MediciNova Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 4.0375 |
| Total Operating Expense | 10.8818 | 13.0271 | 15.5868 | 14.0311 | 14.1783 | 14.2533 |
| Selling/General/Admin. Expenses, Total | 7.36266 | 8.80335 | 9.96101 | 7.95204 | 6.69349 | 5.71529 |
| Research & Development | 3.51917 | 4.22375 | 5.62581 | 6.07904 | 7.48484 | 8.53803 |
| Operating Income | -10.8818 | -13.0271 | -15.5868 | -14.0311 | -14.1783 | -10.2158 |
| Interest Income (Expense), Net Non-Operating | 0.0662 | 0.14521 | 0.93991 | 1.14824 | 0.36118 | 0.14363 |
| Other, Net | -0.04658 | -0.0253 | -0.02289 | -0.04616 | -0.0384 | -0.0595 |
| Net Income Before Taxes | -10.8622 | -12.9072 | -14.6698 | -12.929 | -13.8555 | -10.1317 |
| Net Income After Taxes | -10.866 | -11.8631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
| Net Income Before Extra. Items | -10.866 | -11.8631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
| Net Income | -10.866 | -11.1631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
| Income Available to Common Excl. Extra. Items | -10.866 | -11.8631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
| Income Available to Common Incl. Extra. Items | -10.866 | -11.1631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
| Diluted Net Income | -10.866 | -11.1631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
| Diluted Weighted Average Shares | 32.9867 | 35.137 | 41.1249 | 43.1588 | 44.4134 | 48.5963 |
| Diluted EPS Excluding Extraordinary Items | -0.3294 | -0.33762 | -0.35684 | -0.29986 | -0.31193 | -0.20854 |
| Diluted Normalized EPS | -0.3294 | -0.33762 | -0.35684 | -0.29986 | -0.31193 | -0.20854 |
| Total Extraordinary Items | 0.7 | 0 | ||||
| Revenue | 4.0375 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total revenue | 4 | 0 | 0.0375 | 0 | 0 |
| Revenue | 4 | 0 | 0.0375 | 0 | 0 |
| Total Operating Expense | 4.20153 | 4.30951 | 3.63944 | 2.10283 | 3.41001 |
| Selling/General/Admin. Expenses, Total | 2.05626 | 1.78239 | 1.55082 | 0.32582 | 1.29802 |
| Research & Development | 2.14527 | 2.52712 | 2.08862 | 1.77701 | 2.112 |
| Operating Income | -0.20153 | -4.30951 | -3.60194 | -2.10283 | -3.41001 |
| Interest Income (Expense), Net Non-Operating | 0.03667 | 0.03434 | 0.03615 | 0.03647 | 0.03734 |
| Other, Net | -0.02294 | -0.00897 | -0.01338 | -0.01421 | -0.01374 |
| Net Income Before Taxes | -0.1878 | -4.28414 | -3.57917 | -2.08058 | -3.38642 |
| Net Income After Taxes | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
| Net Income Before Extra. Items | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
| Net Income | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
| Income Available to Common Excl. Extra. Items | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
| Income Available to Common Incl. Extra. Items | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
| Diluted Net Income | -0.1878 | -4.28414 | -3.57917 | -2.08315 | -3.38642 |
| Diluted Weighted Average Shares | 47.5353 | 48.7984 | 48.9878 | 49.0475 | 49.0433 |
| Diluted EPS Excluding Extraordinary Items | -0.00395 | -0.08779 | -0.07306 | -0.04247 | -0.06905 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.00395 | -0.08779 | -0.07306 | -0.04247 | -0.06905 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 24.7038 | 28.3283 | 62.7584 | 64.3046 | 60.7169 | 72.0089 |
| Cash and Short Term Investments | 24.118 | 27.9917 | 62.3134 | 63.7927 | 60.0368 | 71.4309 |
| Cash & Equivalents | 24.118 | 27.9917 | 62.3134 | 63.7927 | 60.0368 | 71.4309 |
| Prepaid Expenses | 0.58581 | 0.33658 | 0.44494 | 0.51192 | 0.68017 | 0.57799 |
| Total Assets | 39.8131 | 43.4191 | 77.2227 | 79.2052 | 75.4191 | 87.4065 |
| Property/Plant/Equipment, Total - Net | 0.09072 | 0.06289 | 0.05313 | 0.44055 | 0.0557 | 0.88178 |
| Goodwill, Net | 9.60024 | 9.60024 | 9.60024 | 9.60024 | 9.60024 | 9.60024 |
| Intangibles, Net | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
| Long Term Investments | 0.61833 | 0.61666 | 0 | |||
| Total Current Liabilities | 1.63104 | 2.88097 | 2.19191 | 2.22824 | 2.19395 | 2.83291 |
| Accounts Payable | 0.36728 | 1.52023 | 0.61675 | 0.45133 | 0.61663 | 0.40274 |
| Accrued Expenses | 1.26377 | 1.36074 | 1.57516 | 1.77691 | 1.57732 | 2.43017 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 5.28121 | 4.77692 | 4.11508 | 4.31055 | 4.09261 | 3.72937 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 1.956 | 0.20179 | 0.20179 | 0.20179 | 0.20179 | 0.20179 |
| Other Liabilities, Total | 1.69416 | 1.69416 | 1.72137 | 1.88052 | 1.69687 | 0.69467 |
| Total Equity | 34.5319 | 38.6421 | 73.1076 | 74.8946 | 71.3265 | 83.6771 |
| Common Stock | 0.03453 | 0.03645 | 0.04208 | 0.04391 | 0.04503 | 0.04904 |
| Additional Paid-In Capital | 364.886 | 380.157 | 429.29 | 444.016 | 454.297 | 476.788 |
| Retained Earnings (Accumulated Deficit) | -330.293 | -341.456 | -356.131 | -369.073 | -382.927 | -393.061 |
| Other Equity, Total | -0.096 | -0.09462 | -0.09315 | -0.09268 | -0.08822 | -0.09888 |
| Total Liabilities & Shareholders’ Equity | 39.8131 | 43.4191 | 77.2227 | 79.2052 | 75.4191 | 87.4065 |
| Total Common Shares Outstanding | 34.5237 | 36.4529 | 42.0813 | 43.9081 | 45.0246 | 49.0433 |
| Property/Plant/Equipment, Total - Gross | 0.5346 | 0.53666 | 0.93841 | 0.57932 | 1.30698 | |
| Accumulated Depreciation, Total | -0.47172 | -0.48353 | -0.49786 | -0.52362 | -0.4252 | |
| Other Long Term Assets, Total | 0.01096 | 0.01096 | 0.05981 | 0.24624 | 0.11549 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 81.4681 | 78.9097 | 76.1601 | 72.0089 | 68.8311 |
| Cash and Short Term Investments | 76.3018 | 77.7923 | 75.0254 | 71.4309 | 67.6953 |
| Cash & Equivalents | 76.3018 | 77.7923 | 75.0254 | 71.4309 | 67.6953 |
| Total Receivables, Net | 4 | ||||
| Accounts Receivable - Trade, Net | 4 | ||||
| Prepaid Expenses | 1.16628 | 1.11744 | 1.13473 | 0.57799 | 1.1359 |
| Total Assets | 96.1007 | 93.6839 | 91.624 | 87.4065 | 84.1752 |
| Property/Plant/Equipment, Total - Net | 0.04893 | 0.06857 | 0.94607 | 0.88178 | 0.83204 |
| Goodwill, Net | 9.60024 | 9.60024 | 9.60024 | 9.60024 | 9.60024 |
| Intangibles, Net | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
| Other Long Term Assets, Total | 0.18343 | 0.30533 | 0.11754 | 0.11549 | 0.11176 |
| Total Current Liabilities | 1.8311 | 2.46657 | 4.20211 | 2.83291 | 2.97624 |
| Accounts Payable | 0.42815 | 0.60716 | 0.64242 | 0.40274 | 0.66525 |
| Accrued Expenses | 1.40295 | 1.85942 | 1.86553 | 2.43017 | 2.31099 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.72927 | 4.44953 | 5.14162 | 3.72937 | 3.8109 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0.20179 | 0.20179 | 0.20179 | 0.20179 | 0.20179 |
| Other Liabilities, Total | 1.69637 | 1.78117 | 0.73772 | 0.69467 | 0.63287 |
| Total Equity | 92.3715 | 89.2343 | 86.4823 | 83.6771 | 80.3643 |
| Common Stock | 0.04877 | 0.04892 | 0.04903 | 0.04904 | 0.04904 |
| Additional Paid-In Capital | 475.532 | 476.678 | 477.506 | 476.788 | 476.869 |
| Retained Earnings (Accumulated Deficit) | -383.115 | -387.399 | -390.978 | -393.061 | -396.448 |
| Other Equity, Total | -0.09504 | -0.09368 | -0.09504 | -0.09888 | -0.10631 |
| Total Liabilities & Shareholders’ Equity | 96.1007 | 93.6839 | 91.624 | 87.4065 | 84.1752 |
| Total Common Shares Outstanding | 48.7685 | 48.9242 | 49.0283 | 49.0433 | 49.0433 |
| Other Current Liabilities, Total | 1.69416 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -10.866 | -11.1631 | -14.6751 | -12.9417 | -13.8539 | -10.1342 |
| Cash From Operating Activities | -6.54621 | -6.92393 | -9.11412 | -9.12499 | -10.8264 | -9.38161 |
| Cash From Operating Activities | 0.01413 | 0.0281 | 0.02588 | 0.02394 | 0.02134 | 0.02615 |
| Non-Cash Items | 4.00277 | 4.47662 | 6.31044 | 4.11265 | 3.17555 | 1.93444 |
| Cash Taxes Paid | 0.00604 | 0.0092 | 0.00601 | 0.01127 | 0.00149 | 0 |
| Changes in Working Capital | 0.30287 | 1.48869 | -0.77535 | -0.31992 | -0.16936 | -1.20794 |
| Cash From Investing Activities | -0.08448 | 0 | 0.62632 | -0.01127 | -0.03649 | -0.02873 |
| Capital Expenditures | -0.08448 | 0 | -0.0102 | -0.01127 | -0.03649 | -0.02873 |
| Cash From Financing Activities | 8.66564 | 10.797 | 42.8088 | 10.6156 | 7.10576 | 20.778 |
| Issuance (Retirement) of Stock, Net | 8.66564 | 10.797 | 42.8088 | 10.6156 | 7.3096 | 20.8964 |
| Foreign Exchange Effects | 0.00635 | 0.00061 | 0.00069 | -0.00005 | 0.0012 | 0.02655 |
| Net Change in Cash | 2.04129 | 3.87371 | 34.3217 | 1.47924 | -3.75589 | 11.3942 |
| Deferred Taxes | -1.75421 | 0 | 0 | |||
| Other Investing Cash Flow Items, Total | 0.63652 | 0 | ||||
| Financing Cash Flow Items | -0.20384 | -0.11837 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -0.1878 | -4.47194 | -8.05111 | -10.1342 | -3.38642 |
| Cash From Operating Activities | -3.85395 | -2.72702 | -5.74264 | -9.38161 | -3.7284 |
| Cash From Operating Activities | 0.00645 | 0.01261 | 0.01978 | 0.02615 | 0.00443 |
| Non-Cash Items | 1.13964 | 1.89554 | 2.63777 | 1.93444 | 0.12623 |
| Changes in Working Capital | -4.81224 | -0.16322 | -0.34907 | -1.20794 | -0.47264 |
| Cash From Investing Activities | 0 | -0.02579 | -0.02873 | -0.02873 | |
| Capital Expenditures | 0 | -0.02579 | -0.02873 | -0.02873 | |
| Cash From Financing Activities | 20.0999 | 20.4897 | 20.7393 | 20.778 | 0 |
| Financing Cash Flow Items | -0.11835 | -0.11837 | -0.11837 | -0.11837 | 0 |
| Issuance (Retirement) of Stock, Net | 20.2183 | 20.608 | 20.8577 | 20.8964 | 0 |
| Foreign Exchange Effects | 0.0191 | 0.01864 | 0.02071 | 0.02655 | -0.0073 |
| Net Change in Cash | 16.2651 | 17.7555 | 14.9886 | 11.3942 | -3.7357 |
| Cash Taxes Paid | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| 3D Investment Partners Pte. Ltd | Investment Advisor | 11.2181 | 5502047 | 0 | 2022-07-08 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.7265 | 1827732 | 0 | 2022-09-30 | LOW |
| EW Healthcare Partners | Venture Capital | 2.2549 | 1105941 | 0 | 2022-09-30 | LOW |
| Iwaki (Yuichi) | Individual Investor | 2.2263 | 1091933 | 0 | 2022-04-18 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.428 | 700379 | -4708 | 2022-09-30 | LOW |
| Citi Investment Research (US) | Research Firm | 0.918 | 450222 | 2265 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8826 | 432873 | 2499 | 2022-09-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.7196 | 352956 | -2967 | 2022-09-30 | HIGH |
| Matsuda (Kazuko) | Individual Investor | 0.6586 | 322996 | 0 | 2022-04-18 | LOW |
| JPMorgan Private Bank (United States) | Bank and Trust | 0.6077 | 298076 | 2700 | 2022-09-30 | LOW |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.3979 | 195147 | 0 | 2022-09-30 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.3752 | 184028 | 0 | 2022-09-30 | LOW |
| Barclays Capital | Research Firm | 0.3228 | 158300 | -22900 | 2022-09-30 | HIGH |
| BofA Global Research (US) | Research Firm | 0.3155 | 154751 | -4700 | 2022-09-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.3054 | 149800 | -11300 | 2022-09-30 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2901 | 142298 | 0 | 2022-09-30 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.2745 | 134656 | 3276 | 2022-09-30 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.2306 | 113113 | -39256 | 2022-09-30 | LOW |
| Newton Investment Management North America, LLC | Investment Advisor | 0.1865 | 91480 | 0 | 2022-09-30 | MED |
| Capricorn Fund Managers Ltd | Investment Advisor | 0.136 | 66716 | 66716 | 2022-12-31 | HIGH |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group +485000+
Traders
65000+
Active clients monthly
$48000000+
Monthly investing volume
$28000000+
Try now Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
MediciNova Company profile
About MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, MediciNova, Inc. revenues increased from $0K to $4M. Net loss decreased 27% to $10.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 48% to $1.1M (expense), Stock-based Compensation in R&D decrease of 41% to $640K (expense).
Equity composition
Common Stock $.001 Par, 12/10, 30M. auth., 12,482,867 issd., less 43,735 Shs. in Treas. @ $1.2M. Insiders 18.15%. 10/06, 1 for 10 reverse stocksplit.
| Industry: | Bio Therapeutic Drugs |
Suite 650
4275 Executive Square
LA JOLLA
CALIFORNIA 92037
US
Income Statement
News
S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023
Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023
Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike
Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.
15:49, 24 January 2023
Alphabet Q4 earnings: has google’s advertising revenue held up despite recession fears?
A preview of Google parent company Alphabet's fourth-quarter earnings after announcing its plans to cut 12,000 jobs.
11:47, 24 January 2023
FX Weekly Outlook: USD/JPY, EUR/USD Analysis
USD, USD/JPY, EUR/USD forecasts for the week ahead.
14:06, 20 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com